SCHEMBL21047951

SCHEMBL21047951

Fc1cccc(SCc2ccccc2)c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.52
MAPT P10636 4/20 0.43
GAA P10253 1/20 0.43
PKM P14618 1/20 0.43
EGFR P00533 1/20 0.41
SLC6A4 P31645 1/20 0.39
KMT2A Q03164 6/20 0.39
MEN1 O00255 5/20 0.39
HSD17B10 Q99714 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTSB P07858 1/20 0.39
TOP2A P11388 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
SAE1 Q9UBE0 1/20 0.38
UBA2 Q9UBT2 1/20 0.38
PTPRC P08575 1/20 0.38
PTPRG P23470 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30634084 1.00 POLB (0.52) POLBMAPTGAAPKMEGFR
SCHEMBL30484939 0.79 POLB (0.52) POLBMAPTGAAPKMSLC6A4
SCHEMBL1118636 0.79 POLB (0.52) POLBMAPTGAAPKMSLC6A4
SCHEMBL21048059 0.79 POLB (0.52) POLBMAPTGAAPKMEGFR
SCHEMBL30634086 0.79 POLB (0.52) POLBMAPTGAAPKMEGFR
SCHEMBL9431344 0.75 POLB (0.47) POLBMAPTEGFRKMT2AMEN1
SCHEMBL28801720 0.75 PTPRG (0.58) POLBMAPTGAAPKMKMT2A
SCHEMBL8373225 0.73 POLB (0.53) POLBMAPTGAAPKMKMT2A
SCHEMBL943207 0.72 TAAR1 (0.34) MAPTGAAKMT2AMEN1
SCHEMBL17712199 0.71 POLB (0.47) POLBMAPTGAAPKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479818-B2 Treatment of fibrosis with IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2025-11-25 US disclosed
US-12404248-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2025-09-02 US disclosed
EP-3707126-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2025-05-14 EP disclosed
US-20240425477-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2024-12-26 US disclosed
EP-4201924-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2024-10-23 EP disclosed
US-20240287004-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2024-08-29 US disclosed
US-12071424-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2024-08-27 US disclosed
US-11945784-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2024-04-02 US disclosed
EP-3891130-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2023-10-25 EP disclosed
EP-3891130-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2023-10-25 EP disclosed
US-20200392106-A1 IRE1 Small Molecule Inhibitors CORNELL UNIVERSITY 2020-12-17 US disclosed
WO-2020232401-A1 COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-11-19 WO disclosed
WO-2020232403-A1 TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-11-19 WO disclosed
EP-3707126-A1 IRE1 SMALL MOLECULE INHIBITORS Cornell University (US) 2020-09-16 EP disclosed
US-10745379-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2020-08-18 US disclosed
US-10745379-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2020-08-18 US disclosed
WO-2020117634-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-06-11 WO disclosed
WO-2020117634-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-06-11 WO disclosed
US-20190169160-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2019-06-06 US disclosed
US-20190169160-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425477-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-20200392106-A1 IRE1 Small Molecule Inhibitors XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-11945784-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-12071424-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-12479818-B2 Treatment of fibrosis with IRE1 small molecule inhibitors XBP1, DDIT3, HSP90B1 POLB 3286/4885MAPT 4228/4885GAA 2332/4885
US-20240287004-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-20190169160-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-12404248-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885
US-10745379-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 POLB 2859/4885MAPT 3493/4885GAA 1747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.